article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. The scope of the problem.

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

Although it has been widely adopted in other industries, the pharmaceutical industry has yet to do so, and most drug production still relies on the longstanding batch manufacturing process. 3 As the pharmaceutical industry shifts its focus to biologics, the investment in CM elements in industry is expected to increase considerably.